The FDA has removed key web pages on clinical trial diversity, including guidance aimed at increasing diverse representation in research. Other resources scrubbed include a podcast on health equity and a discussion paper on medical device trials. These efforts once prioritized equitable access to medicine—what does this mean for the future of diversity in research?
Related Posts
Hoppin’ some islands.

How dangerous is crown heights these days?
Corporate Johny Johny Yes Papa

Additional Posts in Pharma and Biotech
New to Fishbowl?
Download the Fishbowl app to
unlock all discussions on Fishbowl.
unlock all discussions on Fishbowl.



Probably not much. I don't imagine industry is going to up-end their clinical trial strategies or equity priorities because of a toothless EO. Besides, unlike this administration, industry has a good grasp on how DEI done well is good business.
Only time will tell. Some of these big pharmas are publicly traded, if their accounts are being affected, boards of directors are requesting changes let’s see how many of these companies will hold out. I do believe there could be changes for the future at least the next 4 years…